Laboratory research is key to understanding how cancer works. But when scientists discover a new gene or pathway that’s involved in cancer, much more work needs to happen before that translates into new treatments for people with cancer.
The University of Michigan Comprehensive Cancer Center is launching a new Translational Oncology Program to bridge that gap in a more meaningful way and speed promising new treatments through laboratory testing and into clinical trials.
“The University of Michigan is well known for its strength in basic science. Now, we have the opportunity with the Translational Oncology Program to really make a difference in patients’ lives — which is the real reason we are all here,” says Diane Simeone, M.D., who has been named director of the new program.
The program will be housed at the University’s North Campus Research Complex, a 2.1 million square foot facility purchased by the University from Pfizer Corp. The space here will allow Dr. Simeone to bring together cancer researchers from across the campus who are focused on cancer. Up to 40 investigators will eventually be part of this new program, including teams looking at experimental therapeutics, cancer stem cells, molecular imaging and genomics.
Learn more about the new Translational Oncology Program. To find about clinical trials that are currently available, call the nurses at Cancer AnswerLine at 800-865-1125.